specificity in prostate and non-prostate cell lines. J Mol Endocrinol 2000;25:85–96.
43Pausova Z, Abrahamowicz M, Mahboubi A, Syme C, Leonard GT, Perron M, et al: Functional variation in the androgen-receptor gene is associated with visceral adiposity and blood pressure in male adolescents. Hypertension 2010;55:706–714.
44De Naeyer H, Bogaert V, De Spaey A, Roef G, Vandewalle S, Derave W, et al: Genetic variations in the androgen receptor are associated with steroid concentrations and anthropometrics but not with muscle mass in healthy young men. PLoS One 2014;9:e86235.
45Lapauw B, Goemaere S, Crabbe P, Kaufman JM, Ruige JB: Is the effect of testosterone on body composition modulated by the androgen receptor gene CAG repeat polymorphism in elderly men? Eur J Endocrinol 2007;156:395–401.
46Nielsen TL, Hagen C, Wraae K, Bathum L, Larsen R, Brixen K, et al: The impact of the CAG repeat polymorphism of the androgen receptor gene on muscle and adipose tissues in 20-29-year-old Danish men: Odense Androgen Study. Eur J Endocrinol 2010;162:795–804.
47Ibrahim MM: Subcutaneous and visceral adipose tissue: structural and functional differences. Obes Rev 2010;11:11–18.
48Quinkler M, Sinha B, Tomlinson JW, Bujalska IJ, Stewart PM, Arlt W: Androgen generation in adipose tissue in women with simple obesity–a site-specific role for 17beta-hydroxysteroid dehydrogenase type 5. J Endocrinol 2004;183:331–342.
49O’Reilly MW, Kempegowda P, Walsh M, Taylor AE, Manolopoulos KN, Allwood JW, et al: AKR1C3-mediated adipose androgen generation drives lipotoxicity in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2017;102:3327–3339.
50Hazlehurst JM, Oprescu AI, Nikolaou N, Di Guida R, Grinbergs AE, Davies NP, et al: Dual-5α-reductase inhibition promotes hepatic lipid accumulation in man. J Clin Endocrinol Metab 2016;101:103–113.
51Giagulli VA, De Pergola G, Giorgino F, Cignarelli M, Abbaticchio G, Vermeulen A, et al: Increased free testosterone but normal 5 alpha-reduced testosterone metabolites in obese premenopausal women. Clin Endocrinol (Oxf) 1992;36:553–558.
52Fassnacht M, Schlenz N, Schneider SB, Wudy SA, Allolio B, Arlt W: Beyond adrenal and ovarian androgen generation: Increased peripheral 5 alpha-reductase activity in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003;88:2760–2766.
53Vassiliadi DA, Barber TM, Hughes BA, McCarthy MI, Wass JA, Franks S, et al: Increased 5 alpha-reductase activity and adrenocortical drive in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2009;94:3558–366.
54Vandenput L, Mellström D, Lorentzon M, Swanson C, Karlsson MK, Brandberg J, et al: Androgens and glucuronidated androgen metabolites are associated with metabolic risk factors in men. J Clin Endocrinol Metab 2007;92:4130–4137.
55Hemsell DL, Grodin JM, Brenner PF, Siiteri PK, MacDonald PC: Plasma precursors of estrogen. II. Correlation of the extent of conversion of plasma androstenedione to estrone with age. J Clin Endocrinol Metab 1974;38:476–479.
56Eyster KM: The estrogen receptors: an overview from different perspectives. Methods Mol Biol 2016;1366:1–10.
57Simpson ER: Role of aromatase in sex steroid action. J Mol Endocrinol 2000;25:149–156.
58Deslyper JP, Verdonck L, Vermeulen: A Fat tissue: a steroid reservoir and site of steroid metabolism. J Clin Endocrinol Met 1985;61:564–571.
59Sxymczak J, Millewicz A, Thijssen JHH, Blankstein MA, Daroszewski J: Concentration of sex steroids in adipose tissue after menopause. Steroids 1998;62:319–321.
60Blouin K, Richard C, Brochu G, Hould FS, Lebel S, Marceau S, et al: Androgen inactivation and steroid-converting enzyme expression in abdominal adipose tissue in men. J Endocrinol 2006;191:637–649.
61World Health Organization (WHO). Obesity and Overweight. Fact sheet 2016 . Geneva, WHO, 2016. http://www.who.int/mediacentre/factsheets/fs311/en/.
62Eriksson J, Haring R, Grarup N, Vandenput L, Wallaschofski H, Lorentzen E, et al: Causal relationship between obesity and serum testosterone status in men: a bi-directional mendelian randomization analysis. PLoS One 2017;12:e0176277.
63De Maddalena C, Vodo S, Petroni A, Aloisi AM: Impact of testosterone on body fat composition. J Cell Physiol 2012;227:3744–3748.
64Michalakis K, Mintziori G, Kaprara A, Tarlatzis BC, Goulis DG: The complex interaction between obesity, metabolic syndrome and reproductive axis: a narrative review. Metabolism 2013;62:457–478.
65Morelli A, Sarchielli E, Comeglio P, Filippi S, Vignozzi L, Marini M, et al: Metabolic syndrome induces inflammation and impairs gonadotropin-releasing hormone neurons in the preoptic area of the hypothalamus in rabbits. Mol Cell Endocrinol 2014;382:107–119.
66Sarchielli E, Comeglio P, Squecco R, Ballerini L, Mello T, Guarnieri G, et al: Tumor necrosis factor-α impairs kisspeptin signaling in human gonadotropin-releasing hormone primary neurons. J Clin Endocrinol Metab 2017;102:46–56.
67Garvey WT, Mechanick JI, Brett EM, Garber AJ, Hurley DL, Jastreboff AM, et al: American association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice guidelines for medical care of patients with obesity executive summarycomplete guidelines available at https://www.aace.com/publications/guidelines. Endocr Pract 2016;22:842–884.
68Camacho EM, Huhtaniemi IT, O’Neill TW, Finn JD, Pye SR, Lee DM, et al: Age-associated changes in hypothalamic-pituitary-testicular function in middle-aged and older men are modified by weight change and lifestyle factors: longitudinal results from the European Male Ageing Study. Eur J Endocrinol 2013;168:445–455.
69Corona G, Rastrelli G, Monami M, Saad F, Luconi M, Lucchese M, et al: Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: a systematic review and meta-analysis. Eur J Endocrinol 2013;168:829–843.
70Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff
